The role of microglia in Alzheimer's disease: Friend or foe?

Neurobiology of Aging

Volumn 23, Issue 5, 2002, Pages 677-679

  Schenk, D B ^a   Yednock, T ^a  

^a ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; CD40 ANTIGEN; CYCLOOXYGENASE 2; FC RECEPTOR; FREE RADICAL; IBUPROFEN; IMMUNOSTIMULATING AGENT; INDOMETACIN; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PRESENILIN 1; PRESENILIN 2; PROTEIN ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANTIBODY TITER; CELL ACTIVATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOTHERAPY; MICROGLIA; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PHAGOCYTOSIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; SENILE PLAQUE; SPECIES DIFFERENCE; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; HUMANS; MICROGLIA;

EID: 0036753448     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(02)00034-9     Document Type: Note

References (27)

1. Aisen P.S., Davis K.L., Berg J.D., Schafer K., Campbell K., Thomas R.G.et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's disease cooperative study. Neurology. 54:2000;588-593.
2. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M.et al. Inflammation and Alzheimer's disease. Neurobiol. Aging. 21:2000;383-421.
3. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65.
4. Anthony J.C., Breitner J.C., Zandi P.P., Meyer M.R., Jurasova I., Norton M.C.et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology. 54:2000;2066-2071.
5. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H.et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat. Med. 6:2000;916-919.
6. Colton C.A., Chernyshev O.N., Gilbert D.L., Vitek M.P. Microglial contribution to oxidative stress in Alzheimer's disease. Ann. NY Acad. Sci. 899:2000;292-307.
7. Flynn B.L., Theesen K.A. Pharmacologic management of Alzheimer disease. Part III. Nonsteroidal antiinflammatory drugs - emerging protective evidence? Ann. Pharmacotherapy. 33:1999;840-849.
8. Hoozemans J.J., Rozemuller A.J., Janssen I., De Groot C.J., Veerhuis R., Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol. 101:2001;2-8.
9. in't Veld B.A., Launer L.J., Hoes A.W., Ott A., Hofman A., Breteler M.M.et al. NSAIDs and incident Alzheimer's disease. The Rotterdam study. Neurobiol. Aging. 19:1998;607-611.
10. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D.et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;979-982.
11. Jellinger K.A., Bancher C. Neuropathology of Alzheimer's disease: a critical update [review, 107 refs]. J. Neural Trans. Suppl. 54:1998;77-95.
12. Luterman J.D., Haroutunian V., Yemul S., Ho L., Purohit D., Aisen P.S.et al. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch. Neurol. 57:2000;1153-1160.
13. McGeer P.L.M.E.G. Inflammation, autotoxicity and Alzheimer's disease. Neurobiol. Aging. 22:2001;799-809.
14. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J.et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
15. Mortimer JA. New findings consistent with Alzheimer's-NSAIDs link [discussion]. Neurobiol Aging 1998;19:615-8.
16. Pasinetti G.M. Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J. Neurosci. Res. 54:1998;1-6.
17. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T.et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse [see comments]. Nature. 400:1999;173-177.
18. Schenk D.B., Seubert P., Lieberburg I., Wallace J. Beta-peptide immunization: a possible new treatment for Alzheimer's disease. Arch. Neurol. 57:2000;934-936.
19. Schubert P., Ogata T., Marchini C., Ferroni S. Glia-related pathomechanisms in Alzheimer's disease: a therapeutic target? Mech. Ageing Dev. 123:2001;47-57.
20. Selkoe D.J. The genetics and molecular pathology of Alzheimer's disease: roles of amyloid and the presenilins. Neurol. Clin. 18:2000;903-922.
21. Shimohama S., Tanino H., Kawakami N., Okamura N., Kodama H., Yamaguchi T.et al. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 273:2000;5-9.
22. Sisodia S.S. Alzheimer's disease: perspectives for the new millennium. J. Clin. Invest. 104:1999;1169-1170.
23. St. George-Hyslop P.H. Molecular genetics of Alzheimer's disease. Semin. Neurol. 19:1999;371-383.
24. Togo T., Akiyama H., Kondo H., Ikeda K., Kato M., Iseki E.et al. Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases. Brain Res. 885:2000;117-121.
25. Viel J.J., McManus D.Q., Smith S.S., Brewer G.J. Age- and concentration-dependent neuroprotection and toxicity by TNF in cortical neurons from beta-amyloid. J. Neurosci. Res. 64:2001;454-465.
26. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U.et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 414:2001;212-216.
27. Wyss-Coray T., Lin C., Yan F., Yu G.Q., Rohde M., McConlogue L.et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 7:2001;612-618.